The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWalter Reed National Military Medical Center
About this trial
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
Eligibility criteria
Qualifiers
only DOD beneficiaries
adult patients 18 years of age or older
adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease
Disqualifiers
Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation
patients with a history of uncontrolled diabetes mellitus
patients with a history/diagnosis of uncontrolled inflammatory bowel disease
patients under age 18 years
Trial design
Treatments tested in this trial
- Teprotumumab Injection [Tepezza]
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov